Daily Archives: 8 April 2024

Selenium supplementation safeguards against obesity and may prolong lifespan

A study published today in eLife reveals that incorporating selenium into diets shields against obesity and delivers metabolic advantages to mice. This discovery opens the possibility for interventions that mimic the anti-ageing benefits linked to dietary restriction while still allowing individuals to maintain their usual eating habits.

Various diets have been identified to enhance healthspan—the duration of life spent in good health. Limiting dietary methionine, an amino acid, has been confirmed as a method to prolong healthspan in several species, including mammals, not humans. Recent research indicates that the benefits of methionine restriction on healthspan might also apply to humans. While some may find methionine restriction achievable through specific diets, such as veganism, it may not be feasible or appealing to all. In response, researchers from the Orentreich Foundation for the Advancement of Science (OFAS) in Cold Spring, New York, US, set out to develop an alternative that emulates the effects of methionine restriction without necessitating a restricted diet.

A significant hint for this research was that limiting methionine decreases levels of IGF-1, a hormone that regulates energy. If a treatment reduces IGF-1 levels, it also promotes healthspan. Previous studies demonstrated that selenium supplementation lowers IGF-1 levels in rats, making it a promising candidate.

The research team first examined if selenium supplementation could protect against obesity as methionine restriction does. The team provided young male and older female mice with one of three high-fat diets: a standard diet, a methionine-restricted diet, and a standard diet with selenium. The study found that selenium supplementation effectively prevented the weight gain and fat build-up seen in control diet mice, mirroring the effects of methionine restriction.

To investigate the diets’ impact on metabolic changes associated with methionine restriction, the team set up tests that measured four metabolic markers in the mice’s blood. The results were promising, showing significant reductions in IGF-1 and leptin levels, a hormone controlling hunger and energy use, in both male and female mice. These findings suggest that selenium supplementation can replicate most of the benefits of methionine restriction, offering enhancements similar to the healthspan.

To understand the broader implications of selenium supplementation, the team explored its effects on yeast, another organism. They assessed yeast healthspan through two metrics: chronological lifespan, the longevity of dormant yeast, and replicative lifespan, the yeast’s ability to produce offspring. Previous research showed methionine restriction increased yeast’s chronological lifespan, leading the team to investigate if selenium would have a comparable effect. Selenium-enriched yeast demonstrated a 62% increase in chronological lifespan (from 13 to 21 days) and a replicative lifespan extended by nine generations compared to controls. That indicates selenium’s capacity to significantly improve health span, as evidenced by various ageing cell tests.

Jay Johnson, Senior Scientist at OFAS and the study’s senior author, highlights the ageing research community’s aim to find simple, effective interventions to boost human healthspan. The study provides evidence that short-term selenium supplementation, whether from organic or inorganic sources, offers numerous health benefits to mice, particularly in preventing diet-induced obesity. Looking ahead, the research team anticipates these selenium compounds will also thwart age-related diseases and increase mice’s overall lifespan, hoping these advantages will extend to humans.

More information: Jason D Plummer, Spike DL Postnikoff, Jessica K Tyler, Jay E Johnson, Selenium supplementation inhibits IGF-1 signaling and confers methionine restriction-like healthspan benefits to mice, eLife. DOI: 10.7554/eLife.62483

Journal information: eLife

Size Matters: Understanding the Neuroanatomy Behind Trigeminal Neuralgia’s Response to Treatment

The publication in the journal *Cephalalgia*, recognized as the official outlet of the International Headache Society, unveils groundbreaking findings on the neuroanatomical factors affecting treatment outcomes for individuals suffering from trigeminal neuralgia. Led by Dr Tejas Sankar from the University of Alberta, Canada, the research titled “Hippocampal and trigeminal nerve volume predict the outcome of surgical treatment for trigeminal neuralgia” casts a new light on this debilitating condition.

Trigeminal neuralgia (TG), often manifesting as intense facial pain primarily felt in the cheek or jaw, is briefly described in the 3rd Version of the International Classification of Headache Disorders (ICHD-3) as a disorder marked by recurrent, unilateral, electric shock-like pains. These pains are abrupt in onset and cessation, confined to the trigeminal nerve’s distribution, and are provoked by benign stimuli. While it may arise spontaneously, it can also stem from an underlying disorder, with a possibility of accompanying continuous, moderate-intensity pain within the affected nerve’s distribution.

The research delineates two prevalent forms of TN: the classical form, linked with neurovascular compression at the nerve’s root entry zone, and the idiopathic form, which lacks this neurovascular compression. In cases where pharmacological treatments fail, microvascular decompression emerges as a viable surgical alternative.

Dr. Sankar’s hypothesis builds on existing evidence that suggests a consistent reduction in trigeminal nerve volume and cross-sectional area on the afflicted side in TN patients. The research proposes that those failing to respond to surgical interventions may exhibit distinct neuroanatomical characteristics.

The study analyzed 37 patients diagnosed with either classical or idiopathic TN, employing neuroimaging techniques like T2-weighted magnetic resonance imaging (1.5T) performed a year before undergoing microvascular decompression surgery. The focus was on evaluating the trigeminal nerve and other subcortical brain structures, such as the thalamus, hippocampus, and amygdala, due to their roles in the trigeminal sensory relay and as potential factors in the limbic aspects of chronic pain. Comparisons were made between the ipsilateral and contralateral sides relative to the pain location, including total nerve volume and percentage differences.

The findings revealed a 68% success rate among patients post-surgery, which aligns with prior research. Key observations include a larger thalamus volume on the side opposite the pain in all patients; non-responders had a larger intracranial volume, greater trigeminal nerve volume on the side opposite the pain, and a larger contralateral hippocampus volume than responders. Moreover, the contralateral trigeminal nerve and hippocampus volumes indicated treatment outcomes, with larger volumes associated with non-response to treatment. The role of the hippocampus, both ipsilateral and contralateral, was significant in predicting treatment success.

Despite these novel findings, the researchers caution against overly simplistic interpretations of their data. Treatment resistance in chronic pain likely involves complex interactions among multiple brain structures rather than being attributable to a single entity. They advocate for future studies to explore network and connectivity patterns between responders and non-responders, emphasizing the potential of the hippocampus and other limbic structures as integral components of these networks. This approach could offer deeper insights into how chronic pain is modulated, potentially leading to more effective treatment strategies.

This research underscores the importance of the hippocampus in integrating the emotional aspects of chronic pain. It echos findings in other pain-related disorders, such as migraine, where structural brain changes and increased hippocampal connectivity have been observed. These insights enrich our understanding of trigeminal neuralgia and hint at broader implications for treating chronic pain conditions, highlighting the complex interplay between brain structure, emotional processing, and pain perception.

More information: Hayden Danyluk, Esther Kyungsu Lee, Tejas Sankar et al, Hippocampal and trigeminal nerve volume predict outcome of surgical treatment for trigeminal neuralgia, Cephalalgia. DOI: 10.1177/0333102419877659

Journal information: Cephalalgia Provided by International Headache Society